Antonio Benedetti
Director/Board Member bij Cycle Pharmaceuticals Ltd.
Profiel
Antonio Benedetti has worked as a Director at Cycle Pharmaceuticals Ltd.
since 2016.
Actieve functies van Antonio Benedetti
Bedrijven | Functie | Begin |
---|---|---|
Cycle Pharmaceuticals Ltd.
Cycle Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cycle Pharmaceuticals Ltd. is a British privately-owned biotechnology company that focuses on delivering drug treatments and services to the under-served rare disease patient community. The company is based in Cambridge, UK, and their mission is to utilize the latest pharmaceutical technologies to deliver superior drug treatments to better serve rare genetic disease patients. The company specializes in rare metabolic, immunological, and neurological genetic conditions. The company also provides individualized patient support services to meet patient needs swiftly. Cycle Pharmaceuticals works with a variety of partners to support their patients' needs through their named patient program. | Director/Board Member | 25-01-2016 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Cycle Pharmaceuticals Ltd.
Cycle Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cycle Pharmaceuticals Ltd. is a British privately-owned biotechnology company that focuses on delivering drug treatments and services to the under-served rare disease patient community. The company is based in Cambridge, UK, and their mission is to utilize the latest pharmaceutical technologies to deliver superior drug treatments to better serve rare genetic disease patients. The company specializes in rare metabolic, immunological, and neurological genetic conditions. The company also provides individualized patient support services to meet patient needs swiftly. Cycle Pharmaceuticals works with a variety of partners to support their patients' needs through their named patient program. | Health Technology |